Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 6,931 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 6,931 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $45.22, for a total transaction of $313,419.82. Following the completion of the transaction, the director now owns 337,752 shares in the company, valued at $15,273,145.44. This trade represents a 2.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Pro-Dex Price Performance

Shares of NASDAQ PDEX traded down $2.67 during mid-day trading on Wednesday, reaching $41.65. The company had a trading volume of 26,575 shares, compared to its average volume of 28,329. The firm has a market cap of $135.78 million, a price-to-earnings ratio of 27.05 and a beta of 0.56. The business’s 50-day simple moving average is $48.09 and its 200 day simple moving average is $33.44. Pro-Dex, Inc. has a one year low of $16.18 and a one year high of $59.60. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 3.41.

Institutional Investors Weigh In On Pro-Dex

Large investors have recently bought and sold shares of the company. Ritholtz Wealth Management bought a new stake in shares of Pro-Dex during the 4th quarter worth approximately $572,000. JPMorgan Chase & Co. raised its position in Pro-Dex by 2.2% during the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after purchasing an additional 529 shares in the last quarter. Geode Capital Management LLC lifted its stake in Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after purchasing an additional 2,296 shares during the last quarter. FMR LLC boosted its holdings in shares of Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares in the last quarter. Finally, Bard Associates Inc. increased its stake in shares of Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after purchasing an additional 2,031 shares during the last quarter. 15.28% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PDEX. StockNews.com upgraded shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 14th. Ascendiant Capital Markets increased their price target on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, November 11th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.